LRF ANTAGONISTS

Abstract: Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. The peptides have the structure: X-R₁-R₂-R₃-Ser-Tyr-R₄-R₅-Arg-Pro-R₆ wherein X is hydro­ gen or an acyl group having 7 or less carbon atoms; R₁ is dehydro Pro, dehydro D-Pro, Thz or D-Thz; R₂ is D-Phe, D-His, D-Trp, Trp, CI-D-Phe, dichloro-d-Phe, CF₃-D-­ Phe, F-D-Phe, difluoro-D-Phe, AcNH-D-Phe, NO₂-D-Phe, di-­ nitro-D-Phe, Br-D-Phe, dibromo-D-Phe, CH₃S-D-Phe, OCH₃-­ D-Phe or CH₃-D-Phe; R₃ is D-Trp, Trp, D-Phe or D-His; R₄ is Gly or a D-isomer amino acid; R₅ is Leu or N α Me-Leu; and R₆ is Gly-NH₂ or NHCH₂CH₃.

Description: LRF ANTAGONISTS The present invention relates to peptides which inhibit the release of gonadotropins by the pituitary gland in mammalians, including humans and to methods of preventing ovulation and/or inhibiting the release of steroids. More particularly, the present invention is directed to peptides which inhibit gonadal function and the release of the steroidal hormones, progesterone and testosterone. The pituitary gland is attached by a stalk to the region in the base of the brain known as the hypothalamus. The pituitary gland has two lobes, the anterior and the posterior lobes. The posterior lobe of the pituitary gland stores and passes onto the general circulation two hormones manufactured in the hypothalamus, these being vasopressin and oxytocin. The anterior lobe of the pituitary gland secretes a number of hormones, which are complex protein or glyco-protein molecules that travel through the bloodstream to various organs and which, in turn, stimulate the secretion into the blood stream of other hormones from the peripheral organs. In particular, follicle stimulating hormone (FSH) and luteinizing hormone (LH), sometimes referred to as gonadotropins or gonadotropic hormones, are released by the pituitary gland. These hormones, in combination, regulate the functioning of the gonads to produce testosterone in the testes and progesterone and estrogen in the ovaries, and also regulate the production and maturation of gametes. The release of a hormone by the anterior lobe of the pituitary gland usually requires a prior release of another class of hormones produced by the hypothalamus. One of the hypothalamic hormones acts as a factor that trigers the release of the gonadotropic hormones, particularly LH, The hypothalamic hormone which acts as a releasing factor for LH is referred to herein as LRF although it has also been referred to as LH-RH and as GnRH. LRF has been isolated and characterized as a decapeptide having the following structure: p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 Peptides are compounds which contain two or more amino acids in which the carboxyl group of one acid is linked to the amino group of the other acid. The formula for LRF, as represented above, is in accordance with conventional representation of peptides where the amino group appears to the left and the carboxyl group to the right. The position of the amino acid residue is identified by numbering the amino acid residues from left to right. In the case of LRF, the hydroxyl portion of the carboxyl group of glycine has been replaced with an amino group (NH2). The abbreviations for the individual amino acid residues above are conventional and are based on the trivial name of the amino acid: where p-Glu is pyroglutamic acid, His is histidine, Trp is tryptophan, Ser is serine, Tyr is tyrosine, Gly is glycine, Leu is Leucine, Arg is arginine and Pro is proline. Except for glycine, amino acids of the peptides of the invention are of the L-configuration unless noted otherwise. It is known that the substitution of D-amino acids for Gly in the 6-position of the LRF decapeptide provides a peptide material having from about 1 to 35 times greater potency than does LRF to effect the release of LH and other gonadotropins by the pituitary gland of mammalians. The releasing effect is obtained when the LRF analog is administered to a mammalian intravenously, subcutaneously, intramuscularly, orally, intranasally or intravaginally. It is also known that substitution of various amino acids for His (or the deletion of His) at the 2-position of the LRF decapeptide produces analogs having an inhibitory effect on the release of LH and other gonadotropins by the pituitary gland of mammalians. In particular, varying degrees of inhibition of the release of LH are obtained when His is deleted (des His) or replaced by D-Ala, D-Phe or Gly. The inhibitory effect of such peptides modified at the 2-position can be further enhanced when a D-amino acid is substituted for Gly in the 6-position of the decapeptides. For example, the peptide: pGlu-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 is 4 times 2 more potent as an inhibitor for the release of gonadotropins than is the same peptide where Gly is present in the 6-position rather than D-Ala. Some female mammalians who have no ovulatory cycle and who show no pituitary or ovarian defect begin to secrete normal amounts of the gonadotropins LH and FSH after the appropriate administration of LRF. Thus, the administration of LRF is considered suitable for the treatment of those cases of infertility where a functional defect resides in the hypothalamus. There are also reasons for desiring to prevent ovulation in female mammalians, and the administration of LRF analogs that are antagonistic to the normal function of LRF have been used to prevent ovulation. For this reason, analogs of LRF which are antagonistic to LRF are being investigated for their potential use as a contraceptive or for regulating conception periods. It is desired to provide peptides which are strongly antagonistic to endogenous LRF and which prevent secretion of LII and the release of steroids by the gonads of mammals. The present invention provides peptides which inhibit the release of gonadotropins in mammalians, including humans, and also provides methods for inhibiting the release of steroids by the gonads of male and female mammalians. The improved BRF analogs are antagonistic to LRF and have an inhibitory effect on the reproduction processes of mammalians. These analogs may be used to inhibit the production of gonadotropins and sex hormones under various circumstances including precocious puberty, hormone dependent neoplasia, dysmenorrhea and endometriosis. Generally, in accordance with the present invention, peptides have been synthesized which strongly inhibit the secretion of gonadotropins by the pituitary gland of mammalians, including humans, and/or inhibit the release of steroids by the gonads. These peptides are analogs of LRF wherein there is a l-position substitution in the form of either dehydroproline or meta-thiazolidine-2-carboxylic acid, and preferably substituents are also present 2-, 3- and 6-positions. The l-position substituent may be modified so that its alpha amino group contains an acyl group, such as formyl, acetyl, acrylyl, vinylacetyl or benzoyl. Dehydro L-Pro is preferred in the 1-position. Modified D-Phe is preferably present in the 2-position and provides increased antagonistic activity as a result of the specific modifications present in the benzene ring. Single substitutions for hydrogen are preferably made in the para- or 4-position, and double substitutions are made preferably in the 2,4- or the 3,4-positions. The substitutions are most preferably selected from dichloro, methyl, fluoro, difluoro, trifluoromethyl, methoxy, bromo, dibromo, nitro, dinitro, acetylamino and methyl mercapto. D-Trp is preferred in the 3-position, and imBzl D-His or D-Trp or some other lipophilic aromatic D-amino acid is preferred in the 6-position, although Gly or any D-isomer amino acid, e.g. D-Leu and D-Ser(O-t But), may be used. The substitutions in the 7- and 10-positions are optional. Because these peptides are highly potent to inhibit release of LH, they are often referred to as LRF antagonists. The peptides inhibit ovulation of female mammals when administered at very low levels at proestrous and are also effective to cause resorption of fertilized eggs if administered shortly after conception. More specifically, the peptides of the precent invention are represented by the following formula: X-R1-R2-R3 -Ser-Tyr-R4-R5-Arg- Pro-R6 wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R1 is dehydro Pro, dehydro D-Pro, Thz or D-Thz; R2 is D-Phe, D-His, fl-Trp, Trp, Cl-D-Phe, dichloro-D-Phe, CF3-D-Phe, F-D-Phe, difluoro-D-Phe, AcNH-D-Phe, NO2-D-Phe, dinitro-D-Phe, Br-D-Phe, dibromo-D-Phe, CH3S-D-Phe, OCH3-D-Phe or CH3-D-Phe; R3 is D-Trp, Trp, D-Phe or D-His; R4 is Gly or a D-isomer amino acid; R5 is Leu or N Me-Leu; and R6 is Gly-NH2 or NHCH2CH3. By dehydro Pro is meant 3,4 dehydroproline, C5H702N, and when X is an acyl radical, it is attached to the nitrogen. By Thz is meant meta-thiazolidine-2-carboxylic acid, C4H702NS, which can be prepared by the treatment of cysteine hydrochloride with formaldehyde, and for example, Ac-Thz may be prepared by the reaction of Thz with acetic anhydride. The peptides of the present invention can be synthesized by a solid phase technique using a chloromethylated resin a methylbenzhydrylamine resin (MBI4A) or a benzhydrylamine (BIiA) resin. The synthesis is conducted in a manner to stepwise add the amino acids in the chain in the manner set forth in detail in the U.S. Patent No. 4,211,693. Side-chain protecting groups, as are well known in the art, are preferably added to Ser, Tyr, Arg and His before these amino acids are coupled to the chain being built upon the resin. Such a method provides the fully protected intermediate peptidoresin. The intermediates of the invention may be represented as: X ¯Rl-R2-R3-Ser(x )-Tyr(X )-R4-R5- Arg(X4) - Pro-X5 wherein: X is an a-amino protecting group of the type known to be useful in the art in the stepwise synthesis of polypeptides and when X in the desired peptide composition is a particular acyl group, that group may be used as the protecting group. Among the classes of a-amino protecting groups covered by X1 are (1) acyl-type protecting groups, such as formyl (For), trifluoroacetyl, phthalyl, p-toluenesulfonyl (Tos), benzoyl (Bz), benzensulfonyl, o-nitrophenylsulfenyl (Nps), tritylsulfenyl, o-nitrophenoxyacetyl, acrylyl (Acr), chloroacetyl, acetyl (Ac) and y-chlorobutyryl; (2) aromatic urethan-type protecting groups, e.g., benzyloxycarbonyl (Z) and substituted benzyloxycarbonyl, such as p-chloro-benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, -bromobenzyloxycarbonyl and p-methoxybenzyloxycarbonyl; (3) aliphatic urethan protecting qroups, such as tertbutyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl and allyloxycarbonyl; (4) cycloalkyl urethan-type protecting groups, such as cyclopentyloxycarbonyl, adamantyloxycarbonyl and cyclohexyloxycarbonyl; (5) thiourethan-type protecting groups, such as phenylthiocarbonyl; (6) alkyl-type protecting groups, such as allyl (Aly), triphenylmethyl(trityl) and benzyl (Bzl)t (7) trialkylsilane groups, such as trimethylsilane. The preferred a-amino protecting group is Boc when X is hydrogen. X is a protecting group for the alcoholic hydroxyl group of Ser and is selected from the group consisting of acetyl, benzoyl, tetrahydropyranyl, tert-butyl, trityl, benzyl and 2,6-dichlorobenzyl. Benzyl is preferred. X3 is a protecting group for the phenolic hydroxyl group of Tyr selected from the group consisting of tetrahydropyranyl, tert-butyl, trityl, benzyl, benzyloxycarbonyl, 4-bromobenzyloxycarbonyl and 2, 6-dichlorobenzyl. 4. X is a protecting group for the nitrogen atoms of Arg and is selected from the group consisting of nitro, Tos, benzyloxycarbonyl, adamantyloxycarbonyl, 4 and Boc; alternatively X may be hydrogen, which means there are no protecting groups on the side chain nitrogen atoms of arginine. X5 is selected from Gly-O-CH2-[resin support; O-CH2-[resin supports and Gly-NH-[resin support]. The criterion for selecting side chain protecting groups for X2-X4 is that the protecting group must be stable to the reagent under the reaction conditions selected for removing the a-amino protecting group at each step of the synthesis. The protecting group must not be split off under coupling conditions, and the protecting group must be removable upon completion of the synthesis of the desired amino acid sequence under reaction conditions that will not alter the peptide chain. When the X5 group is Gly-O-CH2-[resin support], the ester moiety of one of the many functional groups of the polystyrene resin support is being represented. When the X5 group is Gly-NIl-[resin support], an amide bond connects Gly to BISA resin or to a MBHA resin. When X is acetyl, formyl, acrylyl, vinylacetyl, benzoyl or some other acyl group having 7 carbon atoms or less, it may be employed as the X protecting group for the a-amino group of R1 in which case it can be added before coupling of the last amino acid to the peptide chain. Alternatively, a reaction may be carried out with the peptide on the resin, e.g. reacting with acetic acid in the presence of dicyclohexyl carbodiimide (DCC) or preferably with acetic anhydride. The fully protected peptide can be cleaved from the chloromethylated resin support by ammonolysis, as is well known in the art, to yield the fully protected amide intermediate. Deprotection of the peptide as well as cleavage of the peptide from the benzhydrylamine resin can take ulase at 00C with hydrofluoric acid (HF). Anisole can' be added to the peptide prior to treatment with HF. After the removal of HF, under vacuum, conveniently the cleaved, deprotected peptide is treated with ether, decanted, taken in dilute acetic acid and lyophilized. Purification of the peptide can be effected by ion exchange chromotography on a CMC column, followed by partition chromotography using the elution system: n-butanol; 0.1N acetic acid (1:1 volume ratio) on a column packed with Sephadex G-25,.or by using HPLC,as known in the arts. The peptides of the invention are effective at levels of less than 200 micrograms per kilogram of body weight, when administ?red at about noon on the day of proestrous, to prevent ovulation in female rats. For prolonged suppression of ovulation, it may be necessary to use dosage levels in the range of from about 0.1 to about 5 milligrams per kilogram of body weight. These antagonists are also effective as contraceptives when administered to male mammals on a regular basis. Since these compounds will reduce testosterone levels (an undesired consequence in the normal, sexually active male), it may be reasonable to administer replacement dosages of testosterone along with the LRF antagonist. The following Examples are intended further to illustrate the invention by way of example only. In the Examples, Ac- = acetyl, Bz = benayl, Acr = acrylyl, For = formyl. EXAMPLE I The following peptides having the formula X-dehydro Pro-R2 -D-Trp-Ser -Tyr -D-Trp-R5-Arg-Pro-Gly-NH2 are prepared by the solid phase procedure referred to above. TABLE I PEPTIDE X R2 R5 1 Ac 3,4 C12-D-Phe Leu 2 4 CF3-D-Phe t 3 " 4F-D-Phe " 4 II 4 AcNH-D-Phe " 5 1 4 NO2-D-Phe 6 " 4 Br-D-Phe " 7 n 4 CH3S-D-Phe 8 " 4 OCH3-D-Phe " 9 " 4 CH3-D-Phe 10 n 2,4 C12-D-Phe II 11 Acr 3,4 C12-D-Phe 12 Ac 4 OCH3-D-Phe N MeLeu 13 * 4 CH3-D-Phe I' 14 " 3,4 C12-D-Phe II For purposes of an example, a representative solid phase synthesis of Peptide No. 1 above, which is referred to as [Ac-dehydro Pro , 3,4 C12-D-Phe2ID-Trp3,6]-LBF is set forth hereinafter. This peptide has the following formula: Ac-dehydro Pro-3, 4 C12-D-Phe-D-Trp-Ser-Tyr-D-Trp -Leu-Arq-Pro-Gly-NH2 A RHA resin is used, and Boc-protected Gly is coupled to the resin over a 2-hour period in CH2C12 using a 3-fold excess of Boc derivative and DCC as an activating reagent. The glycine residue attaches to the BKA residue by an amide bond. Following the coupling of each amino acid residue, washing, deblocking and coupling of the next amino acid residue is carried out in accordance with the following schedule using an automated machine and beginning with about 5 grams of resin: STEP REAGENTS AND OPERATIONS MIX TIMES MIN. 1 CH2C12 wash-80 ml. (2 times) 3 2 Methanol(MeOH) wash-30 ml.. (2 times) 3 3 CH2C12 wash-80 ml. (3 times) 3 4 50 percent TFA plus 5 percent 1,2-eth anedithiol in CH2CL2-70 ml. (2 times) 10 5 CH2C12 wash-80 ml. (2 times) 3 6 TEA 12.5 percent in CII2C12-70 ml. (2 times) 5 7 MeOH wash-40 ml. (2 times) 2 8 CH2C12 wash-80 ml. (3 times) 3 9 Boc-amino acid (10 mmoles) in 30 ml. of either DMF or CH2C12, depending upon the solubility of the particular protected amino acid, (1 time) plus DCC (10 mmoles) in CH2C12 30-300 10 MeOH wash-40 ml. (2 times) 3 11 TEA 12.5 percent in CH2C12-70 ml. (1 time) 3 12 MeOH wash-30 ml. (2 times) 3 13 CH2C12 wash-80 ml. (2 times) 3 After step 13, an aliquot is taken for a ninhydrin test: if the test is negative, go back to step 1 for coupling of the next amino acid; if the test is positive or slightly positive, go back and repeat steps 9 through 13. The above schedule is used for coupling of each of the amino acids of the peptide of the invention after the first amino acid has been attached. N a Boc protection is used for each of the remaining amino acids throughout the synthesis. The side chain of Arg is protected with Tos. OBzl is used as a side chain protecting group for the hydroxyl group of Ser, and 2-6 dichlorobenzyl is used as the side chain protecting group for the hydroxyl group of Tyr. N-acetyl-dehydro Pro is introduced as the final amino acid. Boc-Arg(Tos) and Boc-D-Trp, which have low solubility in CH2Cl2, are coupled using DMF CH2C12 mixtures. The cleavage of the peptide from the resin and complete deprotection of the side chains takes place very readily at OOC. with HF. Anisole is added as a scavenger prior to HF treatment. After the removal of HF under vacuum, the resin is extracted with 50% acetic acid, and the washings are lyophilized to provide a crude peptide powder. Purification of the peptide is then effected by ion exchange chromatography on CMC (Whatman CM 32, using a gradient of 0.05 to 0.3M NH40Ac in 50/50 methanol/water) followed by partition chromatography in a gel filtration column using the elution system: n-Butanol; 0.1N Acetic acid (1:1 - volume ratio). The peptides set forth in the foregoing table are assayed in vitro and in vivo. The in vitro test is made using dissociated rat pituitary cells maintained in culture for 4 days prior to the assay. The levels of LH mediated in response to the application of peptides is assayed by specific radioimmunoassay for rat LIY. Control dishes of cells only receive a measure which is 3 nanomolar in LRF: experimental dishes receive a measure 3 nanomolar in LRF plus a measure having a concentration of test peptide ranging from 0.01 to 3 nanomolar. The amount of LH secreted in the samples treated only with LRF is compared with that secreted by the samples treated with the peptide plus LRF. Results are calculated and expressed in Table IA (In Vitro column) as the molar concentration ratio of test peptide to LRF (antagonist/LRF) required to reduce the amount of LH released by 3 nanomolar LRF to 50 percent of the control value (ICR50). The peptides described hereinabove are used to determine effectiveness to prevent ovulation in female rats. In this test, a specified number of mature female Sprague-Dawley rats, each having a body weight from 225 to 250 grams, are injected with either 5 or 10 micrograms of peptide in corn oil at about noon on the day of proestrous. Proestrous is the afternoon before estrous (ovulation). A separate female rat group is used as a control to which the peptide is not administered. Each of the control rat females has ovulation at estrous. As indicated in the In Vivo column, the peptides are significantly effective to prevent ovulation of female rats at a very low dosage, and all of the peptide compositions are considered to be totally effective at a dose of one milligram. TABLE IA In Vitro In Vivo (10pug) In Vivo (5pug) Peptide ICR50 Rats Ovulating Rats Ovulating 1 0.039 0/10 4/7 2 0.070 7/9 3 0.021 0/10 0/10 4 9/10 5 0.011 0/10 2/10 6 0.010 5/7 7 0.030 1/10 7/10 8 0.125 3/10 9 0.044 1/7 9/9 10 5/10 4/7 11 0.048 1/10 4/10 12 0.29 5/10 13 0.11 3/4 14 0.05 1/3 8/10 EXAMPLE II The following peptides having the formula X-Rl-pCl-D¯Phe-D-Trp-Ser-Tyr R4-R5-Arg-Pro-R6 are prepared by the solid phase procedure as generally described in Example I except for No. 20 which is prepared on a chloromethylated resin. TABLE II PEPrTDE X R1 R4 R5 R6 15 Ac dehydro Pro D-Trp Leu Gly-NH2 a 1? 16 N Milieu 17 " dehydro D-Pro " Leu I' 18 " " " N&alpha;MeLeu Na MeLeu 19 Acr dehydro Pro " II 20 Ac dehydro D-Pro " Leu NHCH2CH3 21 Ac Thz D-Trp Leu Gly-NH2 22 " " " N a MeLeu 23 " D-Thz " " II 24 " " U Leu " 25 n dehydro Pro (imBzl)D-His " 26 n dehydro D-Pro " " " 27 " Thz n " " zt 28 " D-Thz n " II The peptides set forth in the foregoing table are assayed in vitro and in vivo. The in vitro test is made using dissociated rat pituitary cells maintained in culture for 4 days prior to the assay. The levels of LII mediated in response to the application of peptides is assayed by specific radioimmunoassay for rat LL. Control dishes of cells only receive a measure which is 3 nanomolar in LRF: experimental dishes receive a measure 3 nanomolar in LRF plus a measure having a concentration of test peptide ranging from 1 to 100 nanomolar. The amount of LH secreted in the samples treated only with LRF is compared with that secreted by the samples treated with the peptide plus LRF. Results are calculated and expressed in Tahle ITA (In Vitro column) as the molar concentration ratio of test peptide to LRF (antagonist/LRF) required to reduce the amount of LH released by 3 nanomolar LRF to 50 percent of the control value (ICR50). Several of the peptides described hereinabove are used to determine effectiveness to prevent ovulation in female rats. In this test, four, seven, nine or ten mature female Sprague-Dawley rats) each having a body weight from 225 to 250 grams, are injected with 0.0 milligram of peptide (unless otherwise indicated) in corn oil at about noon on the day of proestrous. Proestrous is the afternoon before estrous (ovulation). A separate ten female rat group is used as a control to which the peptide is not administered. Each of the ten control rat females has ovulation at estrous. As indicated in the In V vo column, the peptides are significantly effective to prevent ovulation of female rats at a very low dosage, and all of the peptide compositions are considered to be totally effective at a dose of one milligram. TABLE ITA In Vitro In Vivo Peptide ICR50 Rats Ovulating 15 0.043 0/10* 16 0.058 0/7 17 0.19 3/8 18 0.27 5/10** 19 0.03 0/9 20 0.2 21 0,14 5/8 22 0.13 9/10** 23 0.1 24 0.12 25 0.042 4/10 26 0.2 10/10 27 0.15 7/10** 28 0.1 7/10** **0.025 mg. *0.010 mg. EXAMPLE III The following peptides having the formula X-R1 -R2-R3 -5cr -Tyr-D-Trp-R5-Arg-Pro-R6 are prepared by a solid phase procedure generally as descrIbed in Example I, except for No. 37 where a chloromethylated resin is used. TABLE III Peptide X 1 R2 R3 aR5 R6 29 H dehydro-D,L-Pro D-Phe D-Trp N MeLeu Gly-NH2 30 H ,I U leu 31 Ac dehydro-D,L-Pro n U" " 32 H " " " N MeLeu " 33 Ac dehydro-Pro " " Leu 34 Ac dehydro-D-Pro " " II II 35 H dehydro-Pro n " " " 36 H dehydro-D-Pro " II " 37 H dehydro-Pro " SI HCH2CH3 38 Bz dehydro-Pro D-Trp II II 39 For dehydro-Pro n D-Phe " 'I 40 For dehydro-Pro D-His Trp " 41 Acr dehydro-Pro " " " " 42 Bz dehydro-Pro Trp D-His 43 Acr debydro-Pro " D-Trp " " 44 For dehydro-Pro n D-His 45 Bz dehydro-Pro D-His n n n The peptides set forth in the foregoing table are assayed in vitro and in vivo. The in vitro assay is made using four day old primary culture of dispersed rat pituitary cells. The levels of LH mediated in response to the application of peptides is assayed by specific radioimmunoassay for rat LH. Control dishes of cells only receive a measure which is 3 nanomolar in LRF: experimental dishes receive a measure 3 nanamoles of LRF and a concentration of test peptide ranging from 1 to 100 nanomolar. The amount of LH secreted in the samples treated only with LRF is compared with that secreted by the samples treated with the peptide plus LRF. Results are calculated and expressed in Table IIIA (In Vitro column) as the molar concentration ratio of test peptide required to reduce the amount of LH released by the 3 nanomolar LRF to 50 percent of the control value (ICR50). Several of the peptides described hereinabove are used to determine effectiveness to prevent ovulation in female rats. In this test, a number of mature female Sprague-Dawley rats, each having a body weight from 225 to 25G grams, are injected with 0.02 milligram of peptide in corn oil at about noon on the day of proestrous. Proestrous is the afternoon before estrous (ovulation). A separate female rat group is used as a control to which the peptide is not aAninistered. Each of the control rat females has ovulation at estrous. As indicated in the In Vivo column, the peptides are significantly effective to prevent ovulation of female rats at a very low dosage, and all of the peptide compositions are considered to be totally effective at a dose of one milligram. TABLE IIIA In Vitro In Vivo Peptide ICR50 Rats Ovulating 29 0.5:1 4/10 30 0.8:1 7/10 31 0.3:1 1/10 32 0.4:1 2/10 33 0.6:1 0/4* *dose of 0.025 mg. The peDtides of the invention can be adninistered to mammals intravenously, subcutaneously, intramuscularly, orally, intranasally or intravaginally to achieve fertility inhibition and/or control. Effective dosages will vary with the form of administration and the particular species of malamal being treated. An example of one typical dosage form is a physiological saline solution containing the peptide which solution is administered to provide a dose in the range of about 0.1 to 5 mg/kg of body weight. Oral administration of the peptide may be given in either solid form or liquid form. Although the invention has been described with regard to its preferred embodiments, it should be understood that changes and modifications as would be obvious to one having the, oridinary skill in this art may be made without departing from the scope of the invention which is set forth in the claims which are appended hereto. For example, other substitutions known in the art which do not significantly detract from the effectiveness of the peptides may be employed in the peptides of the invention.

Claims: CLAIMS: 1. A peptide or a nontoxic salt thereof, said peptide having the formula: X-Rl-R2-R3-Ser-Tyr-R4-R-Arg-Pro-R6 wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R1 is dehydro Pro, dehydro D-Pro, Thz or D-Thz; R2 is D-Phe, D-His, D-Trp, Trp, C1-D-Phe, dichloro-D-Phe, CF3-D-Phe, F-D-Phe, difluoro-D-Phe, AcNH-D-Phe, NO2-D-Phe, dinitro-D-Phe, Br-D-Phe, dibromo-D-Phe, CH3S-D-Phe, OCH3-D-Phe or CH3-D-Phe; R3 is D-Trp, Trp, D-Phe or D-His;R4 is Gly or a D-isomer amino acid; R5 is Leu or NaMe-Leu; and R6 is Gly-NH2 or NHCH2CH3. 2. A peptide in accordance with Claim 1 wherein R2 is dichloro-D-Phe, 4 CF3-D-Phe, 4 F-D-Phe, difluoro-D-Phe, 4 AcNH-D-Phe, 4 NO2-D-Phe, dinitro--D-Phe, 4 Br-D-Phe, dibromo-D-Phe, 4 CH3S-D-Phe, 4 OCH3-D-Phe or 4 CH3-D-Phe. 3. A peptide in accordance with either Claim 1 or 2 wherein R1 is dehydro-Pro. 4. A peptide in accordance with any of Claims 1, 2 and 3 wherein X is acrylyl. 5. A peptide in accordance with any of Claims 1, 2 and 3 wherein X is acetyl. 6. A peptide in accordance with any of Claims 1 to 5 wherein R3 is D-Trp. 7. A peptide in accordance with any of Claims 1 to 6 wherein R4 is D-Trp. 8. A peptide in accordance with any of Claims 1 to 6 wherein Rd is a lipophilic, aromatic D-isomer amino acid. 9. A peptide in accordance with any of Claims 1 to 8 wherein R5 is Leu. 10. A peptide in accordance with any of Claims 1 to 9 wherein R6 is Gly-NH2. ii. A peptide as claimed in Claim 11 and substantially as hereinbefore specifically identified. 12. A method for the manufacture of a compound having the formula: X-R1-R2-R3-Ser-Tyr-R4-R5-Arg-Pro-R6 wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R1 is dehydro Pro, dehydro D-Pro, Thz or D-Thz; R2 is D-Phe, D-His, D-Trp, Trp, Cl-D-Ph-, dichloro-D-Phe, CF3-D-Phe, F-D-Phe, difluoro-D-Phe, AcNH-D-Phe, NO2-D-Phe, dinitro-D-Phe, Br-D-Phe, dibromo-D-Phe, CH3S-D-Phe, OCH3-D-Phe or CH3-D-Phe; R3 is D-Trp, Trp, D-Phe or D-His; R4 is Gly or a a D-isomer amino acid; R5 is Leu or N Me-lieu; and R6 is Gly-NH2 or NHCH2CH3, the process comprising; (a) forming an intermediate compound having the formula: X -R1-R2-R-Ser(X2)-Tyr-(X3)-R4-R5- Arg(X )-Pro-X wherein X is an a-amino protecting group; X2is a protecting group for the alcoholic hydroxyl group of Ser; X is a protecting group for the phenolic hydroxyl group of Tyr; X4 is a protecting group for the nitrogen atoms of Arg; and X5 is selected from Gly-O-CH2 (resin support), O-CH2-(resin support), Gly-NH-(resin support), Gly-NH2 and NHCH2CH3; (b) splitting off one or more of the groups X1 to X and, if desired, converting a resulting peptide into a nontoxic salt thereof. 13. A method as claimed in Claim 12 and substantially as hereinbefore described in any one of the foregoing specific Examples. 14. A peptide as claimed in Claim 1 and obtained by a process as claimed in Claim 12 or Claim 13. 15. A pharmaceutical composition comprising a peptide as claimed in any one of Claims 1 to 11 and 14 together with a carrier or diluent rendering the composition administrable intravenously, subcutaneously, intramuscularly, orally, intranasally or intravaginally. 1. A method for the manufacture of a compound having the formula: X-R1-RZ-R,-Ser-Tvr R5-Arg-Pro-R6 wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R1 is dehydro Pro, dehydro D-Pro, Thz or D-Thz; R2 is D-Phe, D-IIis, D-Trp, Trp, Cl-D-Phe, dichloro-D-Phe, CF3-D-Phe, F-D-Phe, difluoro-D-Phe, AcNH-D-Phe, NO -D-Phe, dinitro-D-Phe, Br-D-Phe, 2 dibromo-D-Phe, CH3S-D-Phe, OCH3-D-Phe or CH3-D-Phe; R3 is D-Trp, Trp, D-Phe or D-His; R4 is Gly or a D-isomer amino acid; R5 is Leu or NN,e-Leu; and R6 is Gly-NH2 or NHCH2CH3. comprising (a) forming an intermediate compound having the formula: Xl-Rl-Rg-R3-ser(x2)-Tyr-(x3)-R4- R5-Arg(x4-)-pro-x wherein "1 is an a-amino protecting group; X is a protecting group for the alcoholic hydroxyl group of Ser; X3 is a protecting group for the phenolic hydroxyl group of Tyr; X4is a protecting group for the nitrogen atoms of Arg; and X5 is selected from Gly-O-CH2tresin support), O-CH2-tresin support], Gly-NH-tresin support), Gly-NH2 and NHCR2CE3; (b) splitting off one or more of the groups X1 to X5 and, if desired, converting a resulting peptide into a nontoxic salt thereof. 2. A method in accordance with Claim l wherein R2 is dichloro-D-Phe, 4 CF3-D-Phe, 4 F-D-Phe, difluoro-D-Phe, 4 AcNu-D-Phe, 4 NO2-D-Phe, dinitro-D-Phe, 4 Br-D-Phe, dibromo-D-Phe, 4 CH3S-D-Phe, 4 OcH3-D-phe or 4 C113-D-Phe. 3. A method in accordance with either Claim 1 or 2 wherein Rl is dehydro-Pro. 4. A method in accordance with any of Claims 1, 2 and 3 wherein X is acrylyl. 5. A method in accordance with any of Claims 1, 2 and 3 wherein X is acetyl. 6. A method in accordance with any of Claims 1 to 5 wherein R3 is D-Trp. 7. A method in accordance with any of Claims l to 6 wherein R4 is D-Trp. 8. A method in accordance with any of Claims l to 6 wherein R4 is a lipophilic, aromatic D-isomer amino acid. 9. A method in accordance with any-of Claims I to 8 wherein R5 is Leu. 10. A method in accordance with any of Claims 1 to 9 wherein R6 is Gly-NH2.

Inventors: RIVIER, CATHERINE LAURE, RIVIER, JEAN EDOUARD FREDERIC, VALE, WYLIE WALKER, JR.
Applicants: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
Application year: 1981
Main classification: C07C103
IPC codes: A61K38, C07K7, C07K14